SCHEMBL5048437

SCHEMBL5048437

CC(NC(=O)c1ccccc1)C(C)C(=O)N1CCN(c2ccc(Br)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 4/20 0.58
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 4/20 0.47
ALOX5 P09917 1/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.47
ACE2 Q9BYF1 1/20 0.47
USP2 O75604 2/20 0.46
DRD2 P14416 1/20 0.45
DRD3 P35462 1/20 0.45
F2 P00734 2/20 0.45
F10 P00742 2/20 0.45
PRSS1 P07477 1/20 0.45
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4501169 0.86 CCR1 (0.79) CCR1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL3943460 0.81 CCR1 (0.60) CCR1SMN1; SMN2
SCHEMBL3946317 0.81 CCR1 (0.78) CCR1SMN1; SMN2ALDH1A1LMNAACE2
SCHEMBL16234873 0.75 ALDH1A1 (0.61) CCR1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL15164219 0.74 CCR1 (0.79) CCR1NPC1RAB9AMAPTALOX5
SCHEMBL4509271 0.74 CCR1 (0.79) CCR1SMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL4486024 0.74 CCR1 (1.00) CCR1SMN1; SMN2ALDH1A1LMNAF2
SCHEMBL4490841 0.71 CCR1 (0.74) CCR1NPC1RAB9AMAPTALDH1A1
SCHEMBL20639605 0.71 KMT2A (0.49) CCR1MAPTALDH1A1LMNAUSP2
SCHEMBL20639601 0.71 KMT2A (0.49) CCR1MAPTALDH1A1LMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973880-A1 PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Brystol-Myers Squibb Company (US) 2008-10-01 EP disclosed
WO-2007087585-A1 PIPERAZINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2007-08-02 WO disclosed